Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC

Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC

From VJOncology Podcast by VJOncology

April 30, 2026 · 17 min · Episode 224

About this episode

This episode explores the evolving treatment landscape of advanced non-small cell lung cancer with insights from leading experts.

In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.

Topics covered

  • advanced non-small cell lung cancer
  • precision oncology
  • molecular targets
  • emerging therapies
  • treatment sequencing
  • immunotherapy

Keywords

  • NSCLC
  • targeted agents
  • clinical challenges
  • treatment landscape
  • immunotherapy
  • precision oncology
  • BRAF mutations
  • KRAS
  • EGFR

Mentioned in this episode

Organizations: Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, Lausanne University Hospital

More episodes of VJOncology Podcast

Explore listener stats, chart rankings, contacts and more on the VJOncology Podcast podcast page.